Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CENTRAX vs A-POXIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
GABA-A receptor positive allosteric modulator; increases chloride ion influx and neuronal hyperpolarization.
Treatment of anxiety disorders,Short-term relief of anxiety symptoms,Off-label: insomnia, alcohol withdrawal, muscle spasm
Anxiety disorders,Alcohol withdrawal syndrome,Seizure disorders (adjunctive),Preoperative sedation
10-30 mg orally, 3-4 times daily.
GERD: 20 mg orally once daily for 4-8 weeks. Erosive esophagitis: 40 mg once daily for 8 weeks. H. pylori eradication: 20 mg twice daily with amoxicillin and clarithromycin for 14 days.
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Terminal elimination half-life is 12-18 hours (mean 15 hours) in adults with normal renal function. Prolonged to 24-36 hours in elderly or moderate renal impairment (Cr Cl < 50 m L/min).
Hepatic via CYP3A4; active metabolite desmethyldiazepam (nordazepam) with long half-life.
Extensively metabolized in the liver via CYP2C19 (major) and CYP3A4 (minor) to inactive metabolites. CYP2C19 polymorphisms significantly affect clearance.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Renal excretion accounts for 60-70% of elimination, predominantly as unchanged drug. Biliary/fecal excretion accounts for 20-30%, with approximately 10% eliminated in feces as metabolites.
98-99% bound to albumin.
95% bound to albumin.
1.0-2.6 L/kg (mean 1.8 L/kg); extensive tissue distribution, indicating high lipophilicity and tissue sequestration.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive distribution into total body water with accumulation in tissues (brain, liver, kidneys).
Oral: approximately 90-100%.
Oral: 80-90%; Intramuscular: 95-100%; no data for other routes.
GFR 10-50 m L/min: administer 75% of normal dose; GFR <10 m L/min: administer 50% of normal dose.
No dosage adjustment required for mild-to-moderate renal impairment (Cr Cl >30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), maximum dose 20 mg daily.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Mild impairment: no adjustment. Moderate-to-severe (Child-Pugh B/C): maximum dose 20 mg daily.
0.5-1 mg/kg/day in divided doses every 6-8 hours; maximum 40 mg/day.
Approved for GERD in children ≥1 year (weight-based: 0.5-1 mg/kg once daily; maximum 20 mg). Safety in infants <1 year not established.
Initiate at 5 mg 3-4 times daily; titrate cautiously due to increased sensitivity and risk of sedation.
No specific dose adjustment, but monitor renal function and for increased risk of Clostridium difficile infection and osteoporosis-related fractures.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve use for patients with inadequate alternatives.
Risk of dependence and withdrawal reactions; respiratory depression, especially with opioids; CNS depression; impaired psychomotor function; not recommended in severe hepatic impairment; use caution in elderly and debilitated patients.
Risk of dependence and withdrawal reactions; avoid abrupt discontinuation. May cause CNS depression and impair cognitive function. Use caution in hepatic impairment and geriatric patients.
Hypersensitivity to benzodiazepines; narrow-angle glaucoma; severe respiratory insufficiency; myasthenia gravis; severe hepatic impairment; children <6 months; pregnancy (especially first and third trimesters).
Severe hepatic impairment, acute narrow-angle glaucoma, myasthenia gravis, hypersensitivity to benzodiazepines, concurrent use with potent CYP3A4 inhibitors.
Avoid grapefruit and grapefruit juice as they may increase prazepam levels. Limit caffeine intake as it may reduce sedative effects. No significant food restrictions apart from alcohol.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Avoid alcohol. Taking with food may delay absorption but does not affect total bioavailability.
First trimester: Data insufficient; benzodiazepines generally associated with cleft palate risk. Second and third trimesters: Risk of floppy infant syndrome, withdrawal symptoms, and neonatal respiratory depression. Avoid during pregnancy, especially in first and third trimesters.
First trimester: Risk of major malformations (neural tube defects, cleft palate) increased by 2-3 fold. Second/third trimester: Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome. Chronic use: Fetal hydantoin syndrome (craniofacial anomalies, growth deficiency, intellectual disability).
Prazepam and its active metabolite desmethyldiazepam are excreted in breast milk. M/P ratio not established. Potential for infant sedation and withdrawal. Use only if benefit outweighs risk.
Excreted into breast milk; M/P ratio ~0.3-0.5. Infant serum levels may reach subtherapeutic concentrations. Risk of sedation and poor feeding. Consider risk-benefit; monitor infant for drowsiness and weight gain.
Pregnancy may increase clearance of benzodiazepines; consider dose adjustment based on clinical response. No standardized regimen; avoid use if possible.
Enhanced clearance (up to 50% increase) in pregnancy requires dose adjustments to maintain therapeutic levels. Frequent monitoring of free phenytoin levels recommended; total levels may be misleading due to decreased albumin. Postpartum dose reduction likely needed.
CENTRAX (prazepam) is a long-acting benzodiazepine with a slow onset; not ideal for acute anxiety. Use with caution in elderly due to increased risk of falls and cognitive impairment. Avoid in severe hepatic impairment; consider dose reduction in mild-to-moderate hepatic disease. Monitor for tolerance and dependence; limit to short-term use (≤4 weeks). Do not discontinue abruptly; taper to prevent withdrawal seizures.
A-POXIDE is a potent benzodiazepine with rapid onset; use lowest effective dose to minimize tolerance. Monitor for respiratory depression, especially in elderly or those with COPD. Abrupt discontinuation may cause withdrawal seizures; taper gradually over weeks to months. Avoid concurrent use with other CNS depressants including alcohol.
Avoid alcohol and other CNS depressants while taking this medication.,Do not drive or operate heavy machinery until you know how CENTRAX affects you.,Take exactly as prescribed; do not increase dose without consulting your doctor.,Do not stop taking this medicine suddenly; your doctor will help you taper off.,Store at room temperature away from moisture and heat.,Report any suicidal thoughts or mood changes to your healthcare provider immediately.
Do not consume alcohol while taking this medication.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Do not stop taking abruptly; follow your doctor's instructions for tapering the dose.,Inform your doctor if you have a history of substance abuse or respiratory conditions.,Store at room temperature away from moisture and heat.,Take exactly as prescribed; do not increase dose without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CENTRAX vs A-POXIDE, answered by our medical review team.
CENTRAX is a Benzodiazepine that works by Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.. A-POXIDE is a Benzodiazepine that works by GABA-A receptor positive allosteric modulator; increases chloride ion influx and neuronal hyperpolarization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CENTRAX and A-POXIDE depend on the specific clinical indication. These are both Benzodiazepine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CENTRAX is: 10-30 mg orally, 3-4 times daily.. The standard adult dose of A-POXIDE is: GERD: 20 mg orally once daily for 4-8 weeks. Erosive esophagitis: 40 mg once daily for 8 weeks. H. pylori eradication: 20 mg twice daily with amoxicillin and clarithromycin for 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CENTRAX and A-POXIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CENTRAX is classified as Category C. First trimester: Data insufficient; benzodiazepines generally associated with cleft palate risk. Second and third trimesters: Risk of floppy infant syndrome, withdrawal symptoms, a. A-POXIDE is classified as Category C. First trimester: Risk of major malformations (neural tube defects, cleft palate) increased by 2-3 fold. Second/third trimester: Risk of preterm birth, low birth weight, and neonata. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.